The global exosome diagnostic and therapeutic market by the Europe region was valued at $XX million in 2018 and is expected to capture $XX million revenue by the end of 2027 with a CAGR of 27.76% during the forecast period of 2019-2027.

EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FORECAST 2019-2027

Europe Exosome Diagnostic and Therapeutic Market by Application (Diagnostic, Therapeutic) by Product (Instrument, Reagent, Software) by End-user (Cancer Institute, Hospital, Diagnostic Center, Other End-user) by Geography.

Request free sample

The exosomes are cell-derived particles that are secreted upon the fusion of external vesicles with the plasma membrane. The exosome diagnostic and therapeutic products that are defined in the report are essentially the medical devices and other diagnostic instruments, which have very impactful integration into the exosome-based research activities that are carried out to explore the usage of exosomes in the diagnosis of various chronic diseases like cancer, cardiac diseases, etc. The global exosome diagnostic and therapeutic market by the Europe region was valued at $XX million in 2018 and is expected to capture $XX million revenue by the end of 2027 with a CAGR of 27.76% during the forecast period of 2019-2027.

The current research studies have revealed the importance and growth in the exploitation of the nano-sized vesicles called exosomes in the diagnostics and therapeutics market. So, their further performance, safety, and quality are of are also found to be very crucial for the cutting edge clinical research. Therefore, the commercialization and approval of the diagnostic products and therapeutic agents based on exosomes are strictly regulated by numerous agencies which are obstructing the establishment of new product and newer market players in the arena.

The European exosome diagnostic and therapeutic market is in its infantile phase, and it had stood as the second leading market in the global exosome diagnostic and therapeutic market in 2018. In Europe, the rising prevalence of chronic diseases like that of cancer, cardiovascular, and other communicable diseases augmented with proliferated population and lifestyle deviations in the region has further driven the market growth. The growing geriatric population is a major driver for the growth of the healthcare industry since it will raise the demand for healthcare centers and products for the aging patients that includes the increasing diagnostic services involving the cardiovascular, neurodegenerative diseases, musculoskeletal problems and increasing problems associated with urogenital issues that can be withstood with higher efficiency through exosomes based treatments.

Hitachi Chemical Diagnostics, Inc., Malvern Instruments Ltd., MBL International Corporation, System Biosciences (SBI), Exosome Diagnostics Inc., EVOX Therapeutics Ltd., HansaBioMed Life Sciences Ltd. (acquired by Lonza), Qiagen N.V., Thermo Fisher Scientific Inc., Nanosomix Inc., Capricor Therapeutics, Inc., BioCat GmbH, Sistemic Ltd., Codiak BioSciences, and Aethlon Medical, Inc. are the major companies operating in the market, which have been exhaustively profiled in the report.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • DIAGNOSTIC IS THE MAJORLY USED APPLICATION
        • SOFTWARE SEGMENT IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
        • CANCER INSTITUTES HOLD THE LARGEST MARKET SHARE IN TERMS OF END-USER
    1. MARKET DYNAMICS
      • MARKET SCOPE & DEFINITION
      • MARKET DRIVERS
        • INCREASE IN PERVASIVENESS OF CANCER
        • RISING GOVERNMENT AND NON GOVERNMENT INITIATIVES
        • ADVANCEMENT IN TECHNOLOGY
      • MARKET RESTRAINTS
        • CHALLENGES FACED IN THE USAGE OF EXOSOME
        • STRINGENT REGULATION
      • MARKET OPPORTUNITIES
        • INCREASE IN ADOPTION OF INNOVATIVE AND ADVANCED EXOSOME DIAGNOSTIC AND THERAPEUTIC PROCEDURES
      • MARKET CHALLENGES
        • LOW AWARENESS IN THE DEVELOPING COUNTRIES
    1. MARKET BY APPLICATION
      • DIAGNOSTIC
      • THERAPEUTIC
    2. MARKET BY PRODUCT
      • INSTRUMENT
      • REAGENT
      • SOFTWARE
    3. MARKET BY END-USER
      • CANCER INSTITUTE
      • HOSPITAL
      • DIAGNOSTIC CENTER
      • OTHER END-USER
    4. KEY ANALYTICS
      • PORTER’S FIVE FORCES MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF BUYERS
        • BARGAINING POWER OF SUPPLIERS
        • THREAT OF COMPETITIVE RIVALRY
      • EXOSOME ETYMOLOGY
      • PATENT ANALYSIS
      • COMPONENTS OF EXOSOME
      • OPPORTUNITY MATRIX
    5. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • FRANCE
        • THE UNITED KINGDOM
        • ITALY
        • SPAIN
        • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      • COMPANY PROFILES
        • AETHLON MEDICAL, INC.
        • BIOCAT GMBH
        • CAPRICOR THERAPEUTICS, INC.
        • CODIAK BIOSCIENCES
        • EVOX THERAPEUTICS LTD.
        • EXOSOME DIAGNOSTICS INC.
        • HANSABIOMED LIFE SCIENCES LTD. (ACQUIRED BY LONZA)
        • HITACHI CHEMICAL DIAGNOSTICS, INC.
        • MALVERN INSTRUMENTS LTD.
        • MBL INTERNATIONAL CORPORATION
        • NANOSOMIX INC.
        • SISTEMIC LTD.
        • SYSTEM BIOSCIENCES (SBI)
        • THERMO FISHER SCIENTIFIC INC.
        • QIAGEN N.V.

    LIST OF TABLES

    TABLE 1        NOMENCLATURE OF EXOSOME PARTICLES

    TABLE 2        EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    TABLE 3        EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2019-2027 ($ MILLION)

    TABLE 4        EUROPE DIAGNOSTIC MARKET 2019-2027 ($ MILLION)

    TABLE 5        EUROPE THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    TABLE 6        EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2019-2027 ($ MILLION)

    TABLE 7        EUROPE INSTRUMENT MARKET 2019-2027 ($ MILLION)

    TABLE 8        COMMERCIAL KITS AND REAGENTS EXAMPLES FOR THE ISOLATION OF EXOSOME

    TABLE 9        EUROPE REAGENT MARKET 2019-2027 ($ MILLION)

    TABLE 10      EUROPE SOFTWARE MARKET 2019-2027 ($ MILLION)

    TABLE 11      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END-USER 2019-2027 ($ MILLION)

    TABLE 12      EUROPE CANCER INSTITUTE MARKET 2019-2027 ($ MILLION)

    TABLE 13      EUROPE HOSPITAL MARKET 2019-2027 ($ MILLION)

    TABLE 14      EXOSOME ASSOCIATED PROTEIN IN CLINICAL DIAGNOSTICS USAGE

    TABLE 15      EUROPE DIAGNOSTIC CENTER MARKET 2019-2027 ($ MILLION)

    TABLE 16      EUROPE OTHER END-USER MARKET 2019-2027 ($ MILLION)

    TABLE 17      TYPE OF PROTEINS FOUND IN EXOSOMES

    TABLE 18      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)

    LIST OF FIGURES

    FIGURE 1      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    FIGURE 2      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY APPLICATION 2018 & 2027 (%)

    FIGURE 3      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC 2019-2027 ($ MILLION)

    FIGURE 4      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY THERAPEUTIC 2019-2027 ($ MILLION)

    FIGURE 5      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY PRODUCT 2018 & 2027 (%)

    FIGURE 6      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY INSTRUMENT 2019-2027 ($ MILLION)

    FIGURE 7      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REAGENT 2019-2027 ($ MILLION)

    FIGURE 8      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY SOFTWARE 2019-2027 ($ MILLION)

    FIGURE 9      EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY END-USER 2018 & 2027 (%)

    FIGURE 10   EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY CANCER INSTITUTE 2019-2027 ($ MILLION)

    FIGURE 11   EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY HOSPITAL 2019-2027 ($ MILLION)

    FIGURE 12   EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC CENTER 2019-2027 ($ MILLION)

    FIGURE 13   EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY OTHER END-USER 2019-2027 ($ MILLION)

    FIGURE 14   PORTER’S FIVE FORCE MODEL

    FIGURE 15   NUMBER OF PAPERS PUBLISHED ON EXOSOME 2003-2017

    FIGURE 16   EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

    FIGURE 17   GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    FIGURE 18   FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    FIGURE 19   THE UNITED KINGDOM EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    FIGURE 20   ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    FIGURE 21   SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    FIGURE 22   REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • FRANCE
        • THE UNITED KINGDOM
        • ITALY
        • SPAIN
        • REST OF EUROPE
    1. MARKET BY APPLICATION
      • DIAGNOSTIC
      • THERAPEUTIC
    2. MARKET BY PRODUCT
      • INSTRUMENT
      • REAGENT
      • SOFTWARE
    3. MARKET BY END-USER
      • CANCER INSTITUTE
      • HOSPITAL
      • DIAGNOSTIC CENTER
      • OTHER END-USER

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type